BCC 2025 | Novel trends in de-escalating surgical therapy in breast cancer

Terry Mamounas • 14 Mar 2025

BCC 2025

Breast Cancer

Terry Mamounas, MD, MPH, FACS, from the AdventHealth Cancer Institute, Orlando, FL, comments on the trend of de-escalating surgical therapy in breast cancer, particularly in patients with low-risk tumors, where sentinel lymph node biopsy may not be necessary. Prospective randomized clinical trials have shown that omitting sentinel lymph node biopsy does not affect local recurrence in the axilla, and that this approach requires careful balancing with systemic therapy to avoid omitting potentially beneficial treatments. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.